BMS-955176: Difference between revisions
Appearance
Content deleted Content added
tagging a stub for needs sections or lead too short isn't helpful and what content there is is well referenced |
TonyDewitt (talk | contribs) No edit summary |
||
Line 4: | Line 4: | ||
==References== |
==References== |
||
{{ |
{{reflist}} |
||
{{HIVpharm}} |
|||
[[Category:Maturation inhibitors]] |
[[Category:Maturation inhibitors]] |
||
{{antiinfective-drug-stub}} |
Revision as of 22:31, 16 October 2015
![]() | This article has multiple issues. Please help improve it or discuss these issues on the talk page. (Learn how and when to remove these template messages)
|
BMS-955176 is an experimental HIV maturation inhibitor under development by Bristol-Myers Squibb for use in the treatment of HIV infection. By blocking the maturation of the virus, it prevents viral reproduction in host CD4+ T cells.[1] Because it targets a different step of the viral lifecycle, it offers promise for individuals with virus that has become highly resistant to other classes of HIV drugs.[2] Since this drug better handles naturally occurring changes in the Gag protease polyprotein, it is unlikely to promote resistance to itself unlike earlier maturation inhibitors.[3]